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ABSTRACT We investigated the role of CD40-CD40 li-
gand (CD40L) interactions in multiple sclerosis (MS) and
experimental allergic encephalomyelitis (EAE). Activated
helper T cells expressing CD40L (gp39) surface protein were
found in MS patient brain sections, but not in brain tissue
sections of normal controls or patients with other neurolog-
ical diseases. CD40L-positive cells were co-localized with
CD40-bearing cells in active lesions (perivascular infiltrates).
Most of these CD40 bearing cells proved to be of the monocytic
lineage (macrophages or microglial cells), and relatively few
were B cells. To functionally evaluate CD40-CD40L interac-
tions, EAE was elicited in mice by means of proteolipid-
peptide immunization. Treatment with anti-CD40L monoclo-
nal antibody completely prevented the development of disease.
Furthermore, administration of anti-CD40L monoclonal an-
tibody, even after disease onset, shortly before maximum
disability score was reached led to dramatic disease reduction.
The presence of helper T cells expressing CD40L in brain
tissue of MS patients and EAE animals, together with the
functional evidence provided by successful experimental pre-
vention and therapy in an animal model, indicates that
blockade of CD40-CD40L-mediated cellular interactions may
be a method for interference in active MS.
Interactions between CD40, constitutively expressed on B
cells, and CD40 ligand [CD40L; gp39; TBAM (T-B cell
activation molecules); TRAP (tumor necrosis factor-related
activation protein)], transiently expressed on activated CD4+
T cells, are essential for B-cell responses against thymus-
dependent antigens. CD40L provides a number of signals to
the B cell, some of which require additional cytokine stimuli,
such as upregulation of cell surface markers, homotypic ad-
hesion, proliferation, and isotype switching (reviewed in ref.
1). In vivo treatment of mice with anti-CD40L monoclonal
antibody (mAb) prevents thymus-dependent antibody re-
sponses (2, 3), and generation of B-cell memory (4).
Although less well described, CD40-CD40L interactions are
now thought to play a role in activation of cells of the
monocytic lineage as well. Treatment of human monocytes
with granulocyte/macrophage colony-stimulating factor, in-
terleukin 3 (IL-3) or interferon y resulted in the induction of
CD40 mRNA and enhancement of cell surface CD40 protein
expression. CD40 was found to mediate monocyte adhesion to
cells transformed to express CD40L. The CD40L-transfected
cells provided a costimulatory signal for monocytes to produce
tumor necrosis factor a and IL-6 in the presence of granulo-
cyte/macrophage colony-stimulating factor or IL-3 (5).
Adoptive transfer studies have established the crucial role of
CD4+ T-cells in experimental allergic encephalomyelitis
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(EAE), but both B cells and monocytes are considered to be
involved in the pathogenesis of multiple sclerosis (MS) as well.
Active lesions in the central nervous system (CNS) of MS
patients are characterized by mononuclear cell infiltrates. The
infiltrating cells comprise T cells, B cells, and macrophages (6).
About 50% of the mononuclear cells in the perivascular lesions
in the CNS of EAE animals, an animal model considered to
represent the effector phase of MS, are blood-borne mono-
cytes/macrophages (7) and microglial cells (8). In Lewis rats,
in which EAE was induced either by adoptive spleen cell
transfer or by active immunization with CNS white-matter
homogenate, the elimination of macrophages significantly
suppressed the development of EAE neurological signs (7).
This suggests an important functional role for macrophages in
EAE.
Recently, we have detected autoantigen specific B cells in
human cerebellum and cerebrum in situ (9). Anti-myelin basic
protein (MBP)-specific B cells were found in CNS tissue
sections of only MS patients, not in patients with other
neurological diseases nor in CNS tissue sections of normal
controls. It is not clear whether these autoantigen-specific B
cells were activated by CD40L+ helper T (Th) cells locally in
the demyelinated areas of the CNS or in peripheral lymphoid
tissues.
In this study, we investigated whether interactions between
CD40L on activated CD4+ T cells and CD40 on B cells and/or
cells of the monocytic lineage are involved in development and
progression of EAE and MS. Using immunohistochemistry, we
evaluated expression of CD40 and CD40L in CNS tissue
sections of MS autopsy material. Furthermore, functional
experiments blocking CD40-CD40L interactions in a mouse
EAE model were performed. Collectively, our data support
the hypothesis that the CD40-CD40L system is indeed in-
volved in EAE and MS, providing a target for therapeutic
intervention.
MATERIALS AND METHODS
Histochemistry. Human autopsy CNS tissues from patients
with MS (n = 12), normal controls, and controls with other
neurological disease were obtained from the Multiple Sclero-
sis/Control Brain Bank (supported by the Netherlands Foun-
dation for the Support of MS Research; Amsterdam). All
histochemical analyses of both human and mouse tissues were
performed on cryosections (8 ,um) from snap-frozen material.
In a pilot study, selected CNS tissues of MS patients (n = 4)
were used in which anti-MBP-specific B cells (putatively
Abbreviations: CNS, central nervous system; DAS, disability scale; EAE,
experimental allergic encephalomyelitis; mAb, monoclonal antibody;
MBP, myelin basic protein; MS, multiple sclerosis; CD40L, CD40 ligand;
PLP, proteolipid protein; Th, helper T; IL-n, interleukin n.
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bearing CD40) were detected on a previous occasion (9).
CD40L+ cells were detected immunohistochemically in human
tissue by using a CD40-Ig fusion protein, as described (3), and
in the mouse with the mAb MR1 (3, 10) directly labeled with
alkaline phosphatase. Alkaline phosphatase was revealed by
using napthol-AS-MX-phosphate and fast blue BB base re-
sulting in a blue precipitate, as described (11). CD40 was
revealed with a mouse anti-human CD40 antibody (5D12; a
kind gift from M. de Boer, PanGenetics BV, Heemstede, The
Netherlands; ref. 12), followed by rabbit-anti-mouse IgG con-
jugated with horseradish peroxidase (RAMPO, Dako, Den-
mark), and immunochemistry with 3-amino-9-ethylcarbazole
(AEC, Sigma), resulting in a red precipitate, as described (11).
CD40 was revealed in a blue color after incubation with mAb
5D12, followed by horse-anti-mouse-IgG coupled with biotin
(Vector Laboratories), and subsequent application of strepta-
vidin-alkaline phosphatase (GIBCO/BRL). Cells of the mono-
cytic lineage (11-13) were detected by acid-phosphatase staining
demonstrating endogenous enzyme activity in lysosomes by using
naphthol AS-BI phosphate (Sigma), as described (11). CD11b
(complement receptor 3; ref. 13) was revealed in red after
incubation with Leu-15 (Becton Dickinson) followed by
RAMPO and AEC. B cells were demonstrated in red as de-
scribed (9) with mouse anti-human IgG/IgM directly labeled with
horseradish peroxidase and revealed with AEC.
EAE Induction and Anti-CD40L mAb Administration. EAE
was induced according to a standard protocol in three groups
(n = 18) of female SJL/J mice (12-15 weeks old) by two
subcutaneous injections of 75 ,tg, 150 jig, or 300 ,tg of
proteolipid protein (PLP) peptide in the abdominal flanks.
The PLP peptide contained amino acids 139-151 of rat PLP
(14). Peptide synthesis was performed by using 9-fluorenyl-
methoxcarbonyl (Fmoc) amino acids with the 9500 Milligen
synthesizer according to standard protocols. The standard
EAE-induction procedure using this peptide results in the
development of acute EAE, clinically and pathologically iden-
tical to EAE induced by using whole CNS myelin or MBP (15).
The emulsion contained 25 ,ug of Mycobacterium tuberculosis
organisms (H37RA; Difco) in 50 ,ul of Freund's complete
adjuvant and 37.5 ,ug, 75 ,ug, or 150 ,ug of peptide in 50 j.l of
phosphate-buffered saline (PBS; 0.01 M phosphate buffer, pH
7.2/0.9% NaCl). On days 0 and 2, each mouse was injected
intravenously with 200 ,lI of Bordetella pertussis suspension
(1010 organisms per animal). Mice were injected intraperito-
neally with 125 ,ug of hamster anti-CD40L mAb (2, 10) in 200
Al of PBS on days 0, 2, and 4; 4, 6, and 8; or 7, 9, and 11. Mice
of the control groups received 125 ,ug of normal hamster
antibodies (Serva) in 200 Al of PBS. The severity of EAE
clinical signs was evaluated each day and graded according to
discrete criteria (15): Disability scale (DAS) units; grade 0 =
no clinical signs, grade 1 = tail weakness, grade 2 = mild
paraparesis and ataxia of the hind legs, grade 3 = severe
paraparesis or ataxia of the hind legs, grade 4 = moribund,
grade S = death due to EAB. Blood samples were obtained on
days 4, 9, 14, 21, 31, and 40 by tail-vein puncture. Sera were
screened in a standard direct ELISA (16) for the presence of
anti-PLP peptide antibodies by using the PLP peptide at a
concentration of 10 ,ug/ml in PBS for coating of microtiter
plates.
RESULTS
Detection of CD40L+ Th Cells. As shown in Fig. 1A,
CD40L+ cells were detected in CNS tissue sections from MS
patients (n = 12). Cells were shown to be of the Th phenotype
by double staining for CD4 (data not shown). In control CNS
tissue sections from normal individuals (n = 5) or from
Alzheimer patients (n = 5), no cells stained with CD40-Ig
fusion protein were observed (Fig. 1B). Similarly, CD40L-
bearing cells could be demonstrated in cryosections of EAE
mice with either CD40-Ig fusion protein (overlap of CD40-Ig
and MR1 immunochemical staining of mouse tissue was shown
before; ref. 3) or the anti-CD40L antibody MR1 (Fig. 1C; day
12 after induction of disease). CD40L-bearing cells were found
in white matter lesions and not outside these lesions nor in
control animals.
Detection of CD40-Bearing Cells. In Fig. 1 D-I serial
sections of a representative perivascular infiltrate in a cryo-
section of MS brain are shown. From Fig. 1D, it is clear that
a majority of the infiltrating cells bear CD40. From our
previous study on anti-MBP antibody production in MS brain
(9), we would have expected these cells to be CD40-bearing B
cells; however, only a few cells (10-20%) were B cells, on the
basis of double staining for IgM/IgG and CD40 (Fig. 1E).
Staining for either acid phosphatase (Fig. 1 F and G) or CD1 lb
(Fig. 1H) showed that most CD40-bearing cells belonged to the
monocytic lineage. Only a very few of these cells were detected
in control cerebrum tissue sections. Cells expressing CD40 and
cells expressing CD40L were found in close juxtaposition after
double staining (Fig. 11), suggesting ongoing cellular interac-
tions.
Prevention of EAE by Anti-CD40L mAb. Administration of
PLP peptide resulted in EAE of dose-dependent severity.
After EAE induction with 75 ,ug or 300 Ag of PLP peptide(data of 150 ,ug not shown), control mice or those receiving
irrelevant hamster antibodies showed a significant reduction in
body weight (25-30%) from day 11 until day 17 (Figs. 2 Top
and 3 Top; shaded bars), the first clinical signs of EAE
becoming apparent on day 11. Severe disease (most animals
moribund or dead) was induced with all peptide doses. The
highest average DAS score of the control groups in animals in
which EAE was induced with 300 jig of PLP peptide was 3.6,
observed on days 16-23 (Fig. 3 Middle), and a score of 2.3 was
observed on days 15-22 (Fig. 2 Middle) in animals in which
EAE was induced with 75 jig of PLP peptide. Strikingly, no
body-weight reduction was observed in animals which were
treated on days 0, 2, and 4 with 125 ,ug of anti-CD40L mAb,
irrespective of the peptide dose used for disease induction
FIG. 1 (on opposite page). In vivo evidence for involvement of CD40-CD40L interactions in EAE and MS. (A) Red, CD40L. CD40L-positive
cells in a perivascular infiltrate in human MS brain. (X325.) (B) No specifically stained cells. No CD40L-positive cells were found in human brain
tissues from "normal" controls or from patients with other neurological disease. Shown here is a representative section of Alzheimer brain. (X40.)
(C) Blue, CD40L. CD40L-positive cells in a perivascular infiltrate of mouse brain during EAE. (x200.) Note: D-I are serial sections from the same
plaque in human MS brain. (D) Red, CD40. Numerous CD40-positive cells are present. (X65.) (E) Red, IgG/IgM; blue, CD40; violet, double
staining, both IgG/IgM and CD40. Only a few cells positive for CD40 also contain IgG or IgM (arrows). This indicates that only a minority of
CD40-expressing cells in the infiltrates belongs to the B-cell subset (10-20%). (X65.) (F) Red, acid phosphatase. Numerous cells having acid
phosphatase activity in lysosomal compartments are present. This indicates that these cells have phagocytic properties and are therefore
monocytes/macrophages or microglia (monocytic lineage). (x65.) (G) Red, acid phosphatase; blue, CD40. The large majority of cells bearing CD40
on their membrane also have acid phosphatase activity in the cytoplasm. This indicates that CD40-positive cells in infiltrates are presumably
monocytes and/or microglia. (X650). (H) Red, CD11b (CR3); blue, CD40; violet, double staining, both CD11b and CD40. The large majority of
CD40-positive cells also express complement receptor 3. Taken together with the acid phosphatase activity, this indicates that CD40-positive cells
in infiltrates are monocytes or microglia. (X325.) (I) Red, CD40; blue, CD40L. Cells expressing CD40 and cells expressing CD40L are juxtaposed
(stars). (x 130.) This suggests that CD40-CD40L interactions are ongoing in perivascular infiltrates in human MS brain. For technical details of
immunohistochemical staining, see Materials and Methods.
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FIG. 2. Prevention ofEAE induced with low-dose peptide by using
anti-CD40L mAb. EAE was induced with 75 ,ug of PLP peptide in
female SJL/J mice (n = 6) according to a standard procedure. Animals
were treated with anti-CD40L mAb on days 0, 2, and 4 (black bars).
Control mice received normal hamster antibodies on the same days
(hatched bars). The effect of anti-CD40L mAb treatment was moni-
tored by determination of the body weight (Top), by evaluation of
clinical signs (Middle; note: no black bars/no disease), and by deter-
mination of serum anti-PLP peptide antibody responses by standard
direct ELISA (Bottom).
(Figs. 2 Top and 3 Top; black bars). Even more dramatic,
MR1-treated animals showed only minimal or no clinical signs
at both doses of PLP peptide used for EAE induction (Figs. 2
Middle and 3 Middle; note: no or only very low black bars).
Clinical signs in the anti-CD40L-treated mice were only found
when EAE was induced with the highest dose (300 jig) of PLP
peptide and disappeared on day 31, whereas clinical signs of
the control group remained severe (Fig. 3 Middle). In control
animals, anti-PLP peptide serum antibody responses were
observed from day 9 until day 40, with maximal responses on
day 14 (titer = 1433) and 21 (titer = 2710) after EAE induction
with 75 ,ug or 300 ,ug of PLP peptide, respectively. In contrast,
anti-PLP peptide antibody responses in animals treated with
CD40L mAb on days 0, 2, and 4 were severely delayed and
decreased, with highest levels on day 31 (titer = 571) and 40
(titer = 1034) after EAE induction with 75 ,g and 300 jig of
PLP peptide, respectively (Figs. 2 Bottom and 3 Bottom).
Effect of Anti-CD40L Treatment During Disease. Treat-
ment with anti-CD40L mAb around day 6 and day 9 after EAE
0 5 10 I 5 20 25 30 3 5 40
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Average EAE DAS (it = 6)
0 5 10 I S 20 25 30 35 40
Days after EAE induction
Average anti-PLP peptide response (it = 6)
22.2
2.0
1.6
1.4.
1.2.
1.0'
0.8-
0.6
014
0.2
0.0
0 5 10 1 5 20 25 30 35 40
Days after EAE induction
FIG. 3. Prevention ofEAE induced with high-dose peptide by using
anti-CD40L mAb. EAE was induced with 300 ,ug of PLP peptide in
female SJL/J mice (n = 6) according to a standard procedure. Animals
were treated with anti-CD40L mAb on days 0, 2, and 4 (black bars).
Control mice received normal hamster antibodies on the same days
(hatched bars). The effect of anti-CD40L mAb treatment was moni-
tored by determination of the body weight (Top) by evaluation of
clinical signs (Middle; note: only very low black bars/minimal disease),
and by determination of serum anti-PLP peptide antibody responses
by standard direct ELISA (Bottom).
induction with 150 ,ug of PLP peptide still resulted in blockade
of disease by 80% and 67%, respectively, as compared with the
complete inhibition (100%) in animals treated with anti-
CD40L mAb around day 2 (Fig. 4). Of the animals treated with
anti-CD40L, none died due to EAE. In control animals, the
first EAE clinical signs (and death) were found on day 11.
DISCUSSION
This study provides evidence that CD40-CD40L interactions
are involved in development of EAE in mice and MS in man.
Functionally, treatment of mice with antibodies against CD40L
both prevented development of disease (prophylaxis) and
dramatically suppressed clinical signs when treatment was
started after onset of disease (therapy). Histologically, cells
expressing CD40 and CD40L were found in the perivascular
infiltrates in the CNS of both EAE mice and MS patients but
not in control tissues. Double-staining procedures revealed
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FIG. 4. Effect of delayed anti-CD40L treatment on EAE. EAE was
induced with 150 jig of PLP peptide in female SJL/J mice (n = 6)
according to a standard procedure. Animals were treated with anti-
CD40L mAb on days 0, 2, and 4; 4, 6, and 8; or 7, 9, and 11 (black bars).
Control mice received normal hamster antibodies on the same days
(hatched bars). The effect of anti-CD40L mAb treatment was moni-
tored by evaluation of clinical signs. The cumulative DAS scores from
day 12 until day 28 of mice treated with anti-CD40L mAb on days 0,
2, and 4 was set at 100% EAE suppression. Cumulative DAS scores
from day 12 until day 28 of the other groups were related to this
percentage.
that the majority of CD40-expressing cells in human MS brain
were cells of the monocytic lineage, while a minority belonged
to the B-cell subset. Finally, juxtaposition of CD40- and
CD40L-expressing cells in situ was demonstrated, indicative of
ongoing cellular interactions.
The interaction between CD40L on activated CD4+ T cells
and CD40 on B cells has been shown to be indispensable for
antibody responses against thymus-dependent antigens (1-4).
However, recent data indicate that the CD40-CD40L axis is
involved not only in humoral immunity but in development of
some autoimmune diseases as well, such as collagen-induced
arthritis (17) and lupus nephritis (18).
Here, we show that cells expressing CD40L could be found
in perivascular infiltrates of CNS tissue of both EAE mice and
MS patients but not in control tissues. Frequencies of CD40L-
expressing cells in these infiltrates were modest. This is in
accordance with frequencies of CD40L+ cells induced in the
spleen by immunization of mice with thymus-dependent an-
tigen (TNP-KLH)(3), where 1 CD40L+ cell was found per 12
KLH-specific B cells. Cells expressing CD40 were abundantly
present in perivascular infiltrates of MS brain. By using acid
phosphatase and CD1lb (CR3) as markers for monocytes/
macrophages and microglia (8, 13), it was shown that CD40
expression was predominantly restricted to cells of the mono-
cytic lineage, while B cells formed a minority of the CD40+
population.
To functionally assess the role of CD40 and its ligand, we
blocked this cognate interaction in vivo by administration of
anti-CD40L antibody in a mouse EAE model. Treatment with
anti-CD40L mAb during disease induction (days 0-4) com-
pletely prevented development of disease, indicating that
CD40-CD40L interactions play an important role in the
induction phase of EAE. Importantly, delaying treatment with
anti-CD40L mAb by initiating it shortly before maximal clin-
ical disease score was reached, resulted in near-total suppres-
sion of disease (Fig. 4). These results indicate that CD40-
CD40L interactions are not only important in the induction
phase but also during the clinical phase of EAE, implying that
the development of this inflammatory disease of the CNS is
dependent on continuous or repeated CD40-CD40L interac-
tions, as was shown for humoral responses against thymus-
dependent antigens (1-3).
What effector mechanisms are induced by CD40-CD40L
interactions in the CNS during EAE and MS? The immuno-
cytochemical data discussed above clearly showed that the
majority of CD40-bearing cells were macrophages or micro-
glia. In addition, a small subpopulation of CD40+ cells be-
longed to the B-cell lineage. Consequently, CD40L-induced
functions of both macrophages/microglia and B cells should be
considered. With respect to B cells, antibodies specific for or
crossreactive with myelin components may be involved in the
process of demyelination in EAE (see, for example, refs. 19 and
20). However, several findings argue against a central role for
B cells in development of EAE and MS. It has been convinc-
ingly demonstrated that EAE can be adoptively transferred by
T cells but not by B cells (21). Furthermore, we have found only
limited numbers of MBP-specific plasma cells in CNS tissue of
MS patients and EAE rhesus monkeys (9). The current study
demonstrates that the number of immunoglobulin-containing
CD40+ B cells in lymphoid infiltrates of MS brain is also
limited in relation to the total number of infiltrating cells and
the number of CD40+ cells of the monocytic lineage. Finally,
the anti-PLP peptide antibodies found at later time points after
anti-CD40L treatment indicate that, despite intact B-cell func-
tion, no clinical signs develop. Apparently, either B-cell re-
sponses are not crucial to disease induction or B cells/
antibodies become unable to induce disease after a critical
susceptible period.
This leaves macrophages/microglia (CD1l1b, acid phos-
phatase-containing cells: see Fig. 1 D-H) in perivascular
infiltrates as the CD40-bearing population crucial to disease
development. Consistent with this possibility, Huitinga et al.
(7) have elegantly demonstrated that macrophages are re-
quired for development of EAE in rats. What macrophage
effector mechanisms contributing to inflammation and/or
demyelination in the CNS may be activated through CD40
triggering? Alderson et al. (5) have shown that CD40 triggering
of human monocytes induced tumoricidal activity, and in the
presence of appropriate cytokines, tumor necrosis factor a,
IL-6, and IL-8 was produced. In addition, CD40 triggering
induces IL-1 and IL-12 (22, 23) and can enhance nitric oxide
production (24). Interestingly, antibodies against IL-12 pre-
vent development of EAE in mice (25). It remains to be
determined which of these compounds are actually produced
in vivo in response to CD40-CD40L interactions and what
their relative contributions to disease development are.
How does treatment with anti-CD40L antibody prevent
disease development and suppress established disease? As we
discussed before (4), anti-CD40L mAb does not induce unre-
sponsiveness by a direct cytotoxic effect on T cells, and it does
not affect the frequencies of IL-2, IL-4, and interferon -y-pro-
ducing cells in situ (3). Collectively, these observations and the
current study suggest that amelioration ofEAE by anti-CD40L
treatment may result from direct blocking of interaction of
CD40L on activated T cells with CD40 on monocytes/
macrophages and microglial cells.
Alternatively, anti-CD40L antibody may induce Th-cell un-
responsiveness in EAE by interference with the CD40-related
expression of additional costimulatory molecules on antigen-
presenting cells, resulting in impaired antigen presentation.
Other studies support this hypothesis in view of the fact that
the blocking of interactions between B7 family members and
their ligands in vivo induce a state of allo-specific T-cell
unresponsiveness (26). Therefore, receptors like CD40, the
triggering of which was shown to regulate the expression of
Immunology: Gerritse et al.
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B7.1 and B7.2 (27), might play an important role in controlling
tolerance and immunity.
Although further details of the mechanism(s) of action are
clearly needed, the co-localization of CD40-bearing macro-
phages/microglia and CD40L-bearing cells in affected CNS
tissue of patients suggests that CD40-CD40L interactions may
play an important role in the immunopathology of MS. By
analogy with the results obtained in EAE, blockade of CD40-
CD40L interactions should be considered as a method to
interfere in active episodes of MS as well. Preventing CD40-
CD40L interactions is potentially useful in limiting duration,
intensity, and neurological damage of disease exacerbations. A
significant advantage of CD40L as a target for intervention, in
comparison with the constitutively expressed CD40, is its
transient expression restricted to activated CD4+ T cells. This
feature allows targeting of only those T cells actively partici-
pating in the response without affecting the population of T
cells at large.
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